Immunotherapy has revolutionised cancer care, offering new hope for many patients, but it also comes with unpredictable and sometimes serious side effects. Researchers at Yale Cancer Center are working to better understand how to maximise benefits.
Immunotherapy has emerged as the fourth pillar of cancer treatment alongside surgery, radiation and chemotherapy. It works by empowering the immune system to recognise and attack cancer cells that have learned to evade normal immune responses. This approach has dramatically improved survival in cancers such as advanced melanoma, where patients once had very limited options.
Researchers like Harriet Kluger, MD, and Mario Sznol, MD, were pioneers in developing immunotherapy for metastatic melanoma, increasing five-year survival rates in some patients from roughly 5% to more than 50%.
Despite its breakthroughs, immunotherapy isn’t without challenges. Immune-based treatments, especially immune checkpoint inhibitors, can activate immune cells broadly, sometimes triggering inflammation in healthy organs. These immune-related adverse events (irAEs) can affect the lungs, heart, nervous system or gut, and may be life-threatening.
Because toxicities can arise unpredictably and affect any organ, early detection and rapid management are critical. Yale researchers are collaborating across specialties, involving neurologists, cardiologists, pulmonologists and rheumatologists, to identify and treat these side effects sooner, helping patients continue therapy when safe.
The goal now isn’t just to improve outcomes but to refine immunotherapy so it hits cancer cells more selectively and spares normal tissues. This includes research into biomarkers that predict who will benefit most and how immune responses can be modulated safely.
Advances are also underway in newer approaches, like engineered T-cell therapies and next-generation immune targets, that aim to widen the pool of patients who benefit while limiting harmful effects.
For many patients, immunotherapy represents a major advance, extending survival and, in some cases, achieving long-lasting remissions. But clinicians emphasise that the powerful immune activation inherent in these treatments requires careful monitoring, patient education and rapid response to side effects.
As research continues, the balance between efficacy and safety remains at the forefront of improving cancer immunotherapy, aiming to turn more breakthroughs into long-term benefits for patients.
Read the full article here.